MLN0128 (A TORC ½ Inhibitor)

Protocol Number : Millennium Pharmaceuticals C31006
An Open-Label Phase 2 Study of MLN0128 in Combination with Fulvestrant in Women with ER-+/HER2-, Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy – OPEN TO ENROLLMENT

Paclitaxel in Combination with Reparixin Versus Paclitaxel

Protocol Number: Dompe REP0114
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Paclitaxel in Combination with Reparixin Compared to Paclitaxel Alone as Front-Line Therapy for Metastatic Triple-Negative Breast Cancer – OPEN TO ENROLLMENT

Sacituzumab Govitecan versus Physician’s Choice Treatment

Protocol Number: USOncology 16023 (www.clinicaltrials.gov)
An International, Multi-Center, Open-Label, Randomized, Phase 3 Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Tripale-Negative Breast Cancer Who Received at Least Two Prior Treatments – OPEN TO ENROLLMENT

SYD985 (antibody-drug conjugate) versus Physician’s Choice Treatment

Protocol Number: USOncology 17027 (www.clinicaltrials.gov)
A Multi-centre, Open-Label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-Drug Conjugate SYD985 to Physician’s Choice in Patients with HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer – OPEN TO ENROLLMENT